

Ref. No.: JPL/CS/2185/2025

Date: 12<sup>th</sup> May, 2025.

To  
BSE Ltd.,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001.  
Script Code : **524731**

Sub. : **Board Meeting.**Reg.: **Intimation under Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.**

Dear Sir,

In continuation to our letter No. JPL/CS/2165/2025 dated 24<sup>th</sup> March, 2025, kindly note that with reference to the captioned regulation, a Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 20<sup>th</sup> May, 2025, at the Registered Office of the Company, inter-alia:

1. To take on record the audited financial results for the quarter and financial year ended on 31<sup>st</sup> March 2025 and
2. To consider recommendation of Dividend, if any.

Kindly take on record the above.

Thanking you,

Yours faithfully,

For Jenburkt Pharmaceuticals Limited,

ASHISH SHAH

Company Secretary and Compliance Officer.